Strs Ohio Makes New Investment in Boston Scientific Corporation $BSX

Key Points

• Strs Ohio has made a significant investment in Boston Scientific Corporation by acquiring 1,098,632 shares worth approximately $110.8 million during the first quarter, representing about 0.07% of the company's stock.
• Multiple institutional investors are also entering the market, with new positions valued at approximately $25,000 to $31,000 each, totaling 89.07% of the stock owned by institutional investors.
• Analysts have raised their price targets for Boston Scientific, with firms like Robert W. Baird and Barclays setting new targets at $123.00 and $133.00, respectively, indicating a positive outlook for the stock.

Strs Ohio bought a new position in Boston Scientific Corporation (NYSE:BSX - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 1,098,632 shares of the medical equipment provider's stock, valued at approximately $110,830,000. Strs Ohio owned about 0.07% of Boston Scientific as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Investment Management Corp VA ADV bought a new position in shares of Boston Scientific during the 4th quarter valued at about $25,000. Sunbeam Capital Management LLC bought a new position in shares of Boston Scientific during the 4th quarter valued at about $26,000. 1248 Management LLC bought a new position in Boston Scientific during the 1st quarter worth approximately $26,000. Y.D. More Investments Ltd bought a new position in Boston Scientific during the 1st quarter worth approximately $27,000. Finally, Ameriflex Group Inc. bought a new position in Boston Scientific during the 4th quarter worth approximately $31,000. 89.07% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the transaction, the director directly owned 2,081 shares in the company, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock valued at $18,397,457 over the last three months. Insiders own 0.50% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on BSX. Robert W. Baird raised their price target on Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Barclays lifted their price objective on Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. Raymond James Financial lifted their price objective on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research report on Thursday, July 24th. Oppenheimer upgraded Boston Scientific from a "market perform" rating to an "outperform" rating and lifted their price objective for the stock from $118.00 to $125.00 in a research report on Monday. Finally, Royal Bank Of Canada reiterated an "outperform" rating on shares of Boston Scientific in a research report on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $117.79.

Boston Scientific Stock Down 2.6%

Boston Scientific stock opened at $105.32 on Thursday. The firm has a market cap of $156.06 billion, a price-to-earnings ratio of 62.69, a PEG ratio of 2.60 and a beta of 0.65. The stock has a fifty day simple moving average of $104.88 and a two-hundred day simple moving average of $102.24. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company's quarterly revenue was up 22.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.